← Evidence library

BIB_177

Long GV / Robert C et al. Dabrafenib + Trametinib in BRAF V600-mutant metastatic melanoma (COMBI-d, COMBI-v). Lancet 2014/NEJM 2014. Combined PFS ~11 months; ORR ~67%. BRAF V600+ first-line option. [Tasks: 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_177/findings.md (research corpus). This page is a short context summary — not individualised medical advice.